STOCK TITAN
  1. Home
  2. News
  3. TFX
  4. Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month

Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men’s Health Month

Rhea-AI Impact
(No impact)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Teleflex (NYSE: TFX) launches two major initiatives during Men's Health Month to raise awareness about prostate health issues. The company introduced the Prostate Monster ad campaign highlighting benign prostatic hyperplasia (BPH) symptoms and the Prostate Education Express mobile center for physician training and community education. The UroLift System, their leading BPH treatment, has treated over 500,000 men worldwide. The mobile education center will tour major U.S. cities, providing training on both the UroLift System and Barrigel rectal spacer. The Barrigel spacer, used before prostate cancer radiation therapy, has shown 98.5% success in reducing rectal radiation exposure by at least 25%, with average reductions of 85%. The initiatives aim to educate about BPH, which affects 14.1 million treatment-seeking men annually in the US, and promote prostate health awareness.
Teleflex (NYSE: TFX) lancia due importanti iniziative durante il Mese della Salute Maschile per sensibilizzare sui problemi legati alla salute della prostata. L'azienda ha presentato la campagna pubblicitaria "Prostate Monster" che mette in evidenza i sintomi dell'iperplasia prostatica benigna (IPB) e il centro mobile "Prostate Education Express" dedicato alla formazione dei medici e all'educazione della comunità. Il sistema UroLift, il loro principale trattamento per l'IPB, ha trattato oltre 500.000 uomini in tutto il mondo. Il centro educativo mobile farà tappa nelle principali città degli Stati Uniti, offrendo formazione sia sul sistema UroLift che sul distanziatore rettale Barrigel. Il distanziatore Barrigel, utilizzato prima della radioterapia per il cancro alla prostata, ha dimostrato un successo del 98,5% nel ridurre l'esposizione rettale alle radiazioni di almeno il 25%, con riduzioni medie dell'85%. Le iniziative mirano a informare sull'IPB, che colpisce 14,1 milioni di uomini in cerca di trattamento ogni anno negli USA, e a promuovere la consapevolezza sulla salute della prostata.
Teleflex (NYSE: TFX) lanza dos importantes iniciativas durante el Mes de la Salud Masculina para aumentar la conciencia sobre los problemas de salud prostática. La compañía presentó la campaña publicitaria "Prostate Monster" que destaca los síntomas de la hiperplasia prostática benigna (HPB) y el centro móvil "Prostate Education Express" para la formación de médicos y la educación comunitaria. El sistema UroLift, su principal tratamiento para la HPB, ha tratado a más de 500,000 hombres en todo el mundo. El centro educativo móvil recorrerá las principales ciudades de Estados Unidos, ofreciendo capacitación tanto en el sistema UroLift como en el espaciador rectal Barrigel. El espaciador Barrigel, utilizado antes de la radioterapia para el cáncer de próstata, ha demostrado un éxito del 98.5% en reducir la exposición rectal a la radiación en al menos un 25%, con reducciones promedio del 85%. Las iniciativas buscan educar sobre la HPB, que afecta a 14.1 millones de hombres en búsqueda de tratamiento anualmente en EE.UU., y promover la conciencia sobre la salud prostática.
Teleflex(NYSE: TFX)는 남성 건강의 달을 맞아 전립선 건강 문제에 대한 인식을 높이기 위해 두 가지 주요 이니셔티브를 시작했습니다. 회사는 양성 전립선 비대증(BPH) 증상을 강조하는 "Prostate Monster" 광고 캠페인과 의사 교육 및 지역사회 교육을 위한 이동식 교육 센터인 "Prostate Education Express"를 소개했습니다. 그들의 주요 BPH 치료법인 UroLift 시스템은 전 세계적으로 50만 명 이상의 남성을 치료했습니다. 이 이동식 교육 센터는 미국 주요 도시를 순회하며 UroLift 시스템과 Barrigel 직장 스페이서에 대한 교육을 제공합니다. Barrigel 스페이서는 전립선암 방사선 치료 전에 사용되며, 직장 방사선 노출을 최소 25% 이상 줄이는 데 98.5%의 성공률을 보였고 평균 85% 감소 효과를 나타냈습니다. 이 이니셔티브들은 매년 미국에서 치료를 받는 1,410만 명의 남성에게 영향을 미치는 BPH에 대해 교육하고 전립선 건강 인식을 증진하는 것을 목표로 합니다.
Teleflex (NYSE : TFX) lance deux initiatives majeures durant le Mois de la Santé Masculine pour sensibiliser aux problèmes de santé de la prostate. L'entreprise a présenté la campagne publicitaire "Prostate Monster" mettant en lumière les symptômes de l’hyperplasie bénigne de la prostate (HBP) ainsi que le centre mobile "Prostate Education Express" dédié à la formation des médecins et à l’éducation communautaire. Leur système UroLift, principal traitement de l’HBP, a traité plus de 500 000 hommes dans le monde. Le centre mobile d’éducation fera escale dans les grandes villes américaines, offrant une formation sur le système UroLift et le dispositif d’espacement rectal Barrigel. Ce dernier, utilisé avant la radiothérapie du cancer de la prostate, a démontré un taux de réussite de 98,5 % pour réduire l’exposition rectale aux radiations d’au moins 25 %, avec une réduction moyenne de 85 %. Ces initiatives visent à informer sur l’HBP, qui touche 14,1 millions d’hommes en quête de traitement chaque année aux États-Unis, et à promouvoir la sensibilisation à la santé de la prostate.
Teleflex (NYSE: TFX) startet während des Monats der Männergesundheit zwei bedeutende Initiativen, um das Bewusstsein für Prostatagesundheit zu stärken. Das Unternehmen stellte die Werbekampagne "Prostate Monster" vor, die Symptome der benignen Prostatahyperplasie (BPH) hervorhebt, sowie das mobile Bildungszentrum "Prostate Education Express" für die Ausbildung von Ärzten und die Aufklärung der Gemeinschaft. Das UroLift-System, ihre führende BPH-Behandlung, hat weltweit über 500.000 Männer behandelt. Das mobile Bildungszentrum wird große US-Städte bereisen und Schulungen sowohl zum UroLift-System als auch zum Barrigel-Rektalabstandshalter anbieten. Der Barrigel-Abstandshalter, der vor der Strahlentherapie bei Prostatakrebs eingesetzt wird, hat eine Erfolgsquote von 98,5 % bei der Reduzierung der rektalen Strahlenbelastung um mindestens 25 % gezeigt, mit durchschnittlichen Reduktionen von 85 %. Die Initiativen zielen darauf ab, über BPH aufzuklären, von der jährlich 14,1 Millionen Männer in den USA betroffen sind, und das Bewusstsein für Prostatagesundheit zu fördern.
Positive
  • Over 500,000 men have been treated with the UroLift System worldwide
  • Barrigel rectal spacer achieved 98.5% success rate in reducing radiation exposure
  • The company is expanding physician training and education through mobile centers across major US cities
  • Strong market presence with UroLift being the #1 chosen minimally invasive BPH treatment
Negative
  • None.

Timed with National Men’s Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health.

The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment.  

WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced two bold awareness initiatives in conjunction with Men’s Health Month to raise awareness for quality-of-life issues associated with benign prostatic hyperplasia (“BPH”) and the potential rectal toxicity side effects for men who undergo a prostate cancer radiation treatment plan.

The initiative includes a new ad campaign featuring the Prostate Monster, and a mobile training and education center—The Prostate Education Express—which is visiting urology practices, hospitals and academic medical centers across major U.S. cities for the remainder of 2025. These activities are focused on educating physicians and the community on the benefits of treatment with the UroLift™ System, the #1 chosen minimally invasive, outpatient treatment for symptoms of an enlarged prostate, or BPH1, and the benefits of organ spacing using the Barrigel™ rectal spacer in advance of prostate cancer radiation therapy.2

The ad campaign airing on cable networks, streaming platforms, and related digital ads, features the unforgettable “Prostate Monster,” a larger-than-life symbol of the everyday disruption BPH can cause in men’s lives—from interfering with sleep to making simple tasks like mowing the lawn or sitting in traffic uncomfortable. The ads direct viewers to UroLift.com, where men can learn more and take the first step toward relief.

When the prostate grows, it can press against the urethra and block the flow of urine, leading to symptoms like frequent urination, weak stream, and interrupted sleep.3 More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.4

Despite how common BPH is, many men delay treatment. “So many men suffer silently with symptoms that can seriously affect their quality of life,” said Claus Roehrborn, M.D* professor of urology at UT Southwestern Medical Center and primary investigator on many UroLift™ System clinical studies over the past 12 years. “Men need to know they don’t have to ‘just deal with it.’ The UroLift™ System offers rapid symptom relief without the need for ongoing medications.”5,6

As a traveling classroom, training hub, and community engagement center, the Prostate Education Express provides hands-on UroLift™ System and Barrigel™ rectal spacer simulator training at a practice’s front door. The national tour will support training for general practicing physicians. The truck will also host community health talks to educate men about their prostate health and collaborate with advocacy events to amplify BPH awareness across major U.S. cities including New York City, Los Angeles, Chicago, Houston, Dallas, Atlanta, Miami, Washington, DC, San Francisco, and Philadelphia.

“June is Men’s Health Month—a time to shine the spotlight on the unique health challenges men face, including BPH, a non-cancerous progressive health concern that commonly occurs as men age,” said Anthony Parrillo, vice president, Global Marketing, Teleflex Interventional Urology. “Across the U.S., 14.1 million men seek treatment for BPH symptoms annually.1 The national ad and Prostate Education Express initiatives are extensions of our mission to empower the future of healthcare by educating and motivating men to prioritize their prostate health and seek out effective, proven treatment options like the UroLift™ System5 and understand the importance of rectal organ protection in advance of prostate cancer radiation treatment with Barrigel™ rectal spacer2.”

A clinical study found that 98.5 percent of men who were treated with Barrigel™ rectal spacer met the primary endpoint of achieving at least a 25 percent reduction in radiation to the rectum.2 Patients who met the primary endpoint averaged an 85 percent reduction in radiation to the rectum, and Barrigel™ rectal spacer is proven superior in the reduction of acute and long-term Grade 2+ GI toxicity at 3 and 6 months compared to control.2 More than 50,000 men have been treated with Barrigel™ rectal spacer, the first and only hyaluronic acid rectal spacer.2,7,8,9,10

For more information about the UroLift™ System, visit www.UroLift.com.

About the UroLift™ System
The UroLift™ System is a minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). It is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside U.S.). The UroLift™ System permanent implants, which can be delivered during an outpatient procedure,11 relieve prostate obstruction without heating, cutting, destruction of, or removing prostate tissue. The UroLift™ System can be used to treat a broad spectrum of anatomies, including obstructive median lobe.12 It is the only leading BPH procedure shown to not cause new onset, sustained erectile or ejaculatory dysfunction.**13-14 A study conducted over 5 years showed a low retreatment rate of about 2-3% per year, or a total of 13.6 percent over the course of the study, demonstrating UroLift™ System durability.5 Most common side effects are temporary and can include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence.6 Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Individual results may vary. The prostatic urethral lift procedure (using the UroLift™ System) is recommended for the treatment of BPH in both the 2021 American Urological Association and 2022 European Association of Urology clinical guidelines. More than 500,000 men have been treated with the UroLift™ System in select markets worldwide.4 Learn more at www.UroLift.com.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

About Barrigel™ Rectal Spacer
Barrigel™ rectal spacer is the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect the rectum during radiation therapy treatment for prostate cancer.2 Barrigel™ rectal spacer is made from Non-Animal Stabilized Hyaluronic Acid (NASHA).16

Hyaluronic acid is a substance naturally present in the human body and is highly biocompatible and fully absorbable. NASHA has a proven history of safety and efficacy in a wide variety of medical applications in men, women and children worldwide.15,17

Barrigel™ rectal spacer has been proven to significantly reduce unwanted side effects from prostate cancer radiation therapy2 and is cleared for rectal spacing in the United States, Australia, and Europe.18 Barrigel™ rectal spacer is indicated for prostate cancer patients with T1-T3b disease. For more information about Barrigel™ rectal spacer, please visit https://barrigel.com/hcp/barrigel-control-matters.

Barrigel™ Rectal Spacer Important Safety Information
Barrigel™ rectal spacer is intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and, in creating this space, it is the intent of Barrigel™ rectal spacer to reduce the radiation dose delivered to the anterior rectum. Barrigel™ rectal spacer is composed of biodegradable material and maintains space for the entire course of prostate radiotherapy treatment and is intended to be absorbed by the patient’s body over time.

Barrigel™ rectal spacer should only be administered by qualified and properly trained physicians with experience in ultrasound guidance and injection techniques in the urogenital/pelvic area.

As with any medical treatment, there are some risks involved with the use of Barrigel™ rectal spacer. Potential complications associated with the use of Barrigel™ rectal spacer include, but are not limited to: pain associated with Barrigel™ rectal spacer injection; needle penetration of the bladder, prostate, rectal wall, rectum, or urethra; injection of Barrigel™ rectal spacer into the bladder, prostate, rectal wall, rectum, urethra, or intravascularly; local inflammatory reactions; infection; urinary retention; rectal mucosal damage, ulcers, necrosis; bleeding; constipation; and rectal urgency. More information on indications, contraindications, warnings and instructions for use can be found in the Instructions For Use at www.barrigel.com. Individual results may vary.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.

About Teleflex Incorporated
As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management’s current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. All other trademarks are the property of their respective owners.

© 2025 Teleflex Incorporated. All rights reserved.

References

*Paid consultants of Teleflex.
**No instances of new, sustained erectile or ejaculatory dysfunction in the L.I.F.T. pivotal study
†Study sponsored by Palette Life Sciences, now part of Teleflex.

  1. U.S. 2023 estimates based on US Market Model 2023-25 (3-14-23 FINAL), which is in part based on Symphony Health PatientSource® 2018-22, as is and with no representations/warranties, including accuracy or completeness.
  2. Mariados NF, Orio PF III, Schiffman Z et al. Hyaluronic acid spacer for hypofractionated prostate radiation therapy: A randomized clinical trial. JAMA Oncol. 2023: e1-e8.†
  3. Speakman, BJUI 2014.
  4. Management estimate based on product sales as of June 2024. Data on file. Teleflex Interventional Urology.
  5. Roehrborn, Can J Urol 2017.
  6. Roehrborn, J Urol 2013
  7. Mariados N, Sylvester J, Shah D et al. Int J Radiat Oncol Biol Phys (2015).
  8. Song D et al, Int J Radiat Oncol Biol Phys (2024).
  9. Data on file. As of 10/01/2024
  10. Management estimate based on product sales as of January 2025. Data on file. Teleflex Interventional Urology.
  11. Shore, Can J Urol 2014
  12. Rukstalis, Prostate Cancer Prostatic Dis 2018
  13. AUA BPH Guidelines 2003, 2020
  14. McVary, Urology 2019
  15. Svatos M, Chell E, Low DA, et al. Symmetry, separation, and stability: Physical properties for effective dosimetric space with a stabilized hyaluronic acid spacer. Med Phys. 2024; https://doi.org/10.1002/mp.17292 †
  16. Barrigel Injectable Gel Instructions for Use (2022).
  17. Restylane® celebrates 25 years of natural-looking results with its signature line of hyaluronic acid fillers. 2021. Available at: https://www.prnewswire.com/news-releases/restylane-celebrates-25-years-of-natural-looking-results-with-its-signature-line-of-hyaluronic-acid-fillers-301388779.html. Accessed Sept 30, 2021.
  18. Data on file Teleflex. 2025.

MAC03104-01 Rev A

Contacts:
Teleflex
Lawrence Keusch
Vice President, Investor Relations and Strategy Development
investor.relations@teleflex.com
610-948-2836

Media Contact:
Glenn Silver
Partner National Media Relations Specialist
glenn.silver@finnpartners.com
646-871-8485


FAQ

What are the two new initiatives launched by Teleflex (TFX) for Men's Health Month 2025?

Teleflex launched the Prostate Monster ad campaign to raise BPH awareness and the Prostate Education Express mobile training center for physician education and community outreach.

How many men have been treated with Teleflex's UroLift System globally?

More than 500,000 men have been treated with the UroLift System in select markets worldwide.

What is the success rate of Teleflex's Barrigel rectal spacer in radiation reduction?

98.5% of patients achieved at least a 25% reduction in radiation to the rectum, with average reductions of 85%.

How many men in the US seek treatment for BPH symptoms annually?

According to Teleflex, 14.1 million men seek treatment for BPH symptoms annually in the United States.

Which major US cities will the Teleflex Prostate Education Express visit in 2025?

The mobile center will visit New York City, Los Angeles, Chicago, Houston, Dallas, Atlanta, Miami, Washington DC, San Francisco, and Philadelphia.
Stock TFX logo
Teleflex Inc

NYSE:TFX

TFX Rankings

#1233 Ranked by Market Cap
#1809 Ranked by Dividends

TFX Latest News

Jun 12, 2025
New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients
May 19, 2025
Teleflex Publishes 2024 Global Impact Report
May 15, 2025
Teleflex Showcases New Clinical Data Presented at the 2025 American Urological Association (AUA) Annual Meeting
May 13, 2025
New Retrospective Study Reports Significantly Reduced Post-Operative GERD Rates with the Titan SGS™ Stapler from Teleflex Compared with Multi-Fire Staplers in Sleeve Gastrectomy
May 12, 2025
Teleflex Announces Quarterly Dividend

TFX Stock Data

5.37B
44.04M
0.34%
102.05%
2.41%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
WAYNE

Related Articles

Continue reading with these related stories

View All Latest News